Skip main navigation

Butyrate Regulates COVID-19–Relevant Genes in Gut Epithelial Organoids From Normotensive Rats

Originally publishedhttps://doi.org/10.1161/HYPERTENSIONAHA.120.16647Hypertension. 2021;77:e13–e16

It is increasingly evident that patients with hypertension are at high risk for coronavirus disease 2019 (COVID-19) and exhibit gastrointestinal symptoms suggesting that impaired gut-lung communications could be responsible, at least in part, for the multiorgan pathologies including cardiovascular manifestations of this disease.1 Higher expression of ACE2 (angiotensin-converting enzyme-2) and TMPRSS2 (transmembrane protease serine-2), key molecules in severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection, in gut epithelium from spontaneously hypertensive rats supports this view.2 Finally, changes in gut microbiome associated with short-chain fatty acids, particularly butyrate, is found in both hypertension and COVID-19.1 Butyrate is an HDAC (histone deacetylase) inhibitor that maintains acetylation of histones, affecting chromatin organization and gene expression. Therefore, we sought to test the hypothesis that increased risk of COVID-19 in hypertension could, in part, be due to cumulative depletion of butyrate-producing gut bacteria leading to decreases in butyrate.1 Therefore, treatment with this short-chain fatty acid would regulate ACE2 and its partners influencing antiviral genes. This could be critical in the control of gut viral infection and rebalancing of the gut-lung axis.

Results and Discussion

We performed high-throughput RNA sequencing to determine the effects of butyrate on transcriptional program of colonic organoids. We observed 4526 upregulated genes (Pink dots) and 3167 downregulated genes (purple dots) in butyrate-treated organoids (Figure [A]). Many of these genes were related to SARS-CoV-2 infection: reads per kilobase per million of Ace2 and Tmprss2 that facilitate SARS-CoV-2 entry into host cells were both significantly decreased by butyrate and quantitative polymerase chain reaction confirmed this observation (Figure [B]/[C]). In contrast, Adam17, a metallopeptidase involved in shedding of ACE2, was upregulated by butyrate (Figure [B]/[C]). These data suggest that butyrate could suppress viral infectivity by decreasing membrane ACE2, via downregulating its transcription and increasing its shedding and decreasing activation of viral spike protein. Butyrate increased expression of ACE (Figure [B]/[C]), which could have deleterious or beneficial consequences: increased angiotensin-II is vasoconstrictive while decreased bradykinin is beneficial in controlling inflammation in patients with COVID-19.1 Bradykinin-B2 receptor antagonist, icatibant, improves oxygenation in early-stage of COVID-19.1 HMGB1 (high-mobility group protein-1) regulates transcription under conditions of stress and is critical for SARS-CoV-2 replication at the postentry phase.3 We found reads per kilobase per million of Hmgb1 decreased ≈5-fold by butyrate (Figure [B]/[C]). HMGB1 protein was decreased ≈3-fold by butyrate (Figure [E]). These results indicate that butyrate may control SARS-CoV-2 replication through downregulation of Hmgb1 expression.

Figure.

Figure. Butyrate regulates severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and TLR (toll-like receptor) antiviral pathway relevant genes in gut epithelium. Colonic 3-dimensional (3D) organoid culture: Primary colonic crypts were isolated from proximal colons of male 14-wk-old Wister Kyoto rats (WKY, Charles River) with gentle cell dissociation reagent (STEMCELL Technologies) including 2 mmol/L EDTA for 50 min, grown and maintained as 3D-spheroid cultures in Matrigel (BD Biosciences) containing organoids growth medium (STEMCELL Technologies) with growth factors (Noggin, hepatocyte growth factor, fibroblast growth factor and insulin-like growth factor-I; Biolegend), as described previously.2 Colonic organoids were cultured for 4 d, then treated with 3.0 mmol/L butyrate (Sigma-Aldrich) for 24 h in following experiments. RNA sequencing: Total RNA was extracted from colonic organoids with RNeasy Plus Mini Kit (Qiagen). cDNA was generated using a SMART-Seq HT kit (Takara Bio) and RNA-Seq libraries were constructed with Nextera DNA Flex Library Prep kit and Nextera DNA Unique Dual Indexes Set A (Illumina) and sequenced on NovaSeq6000 instrument (Illumina) at the University of Florida NextGen DNA Sequencing Core Facility. RNA-seq analysis was performed using CLC genomics workbench (Qiagen). A, Volcano plot of genes altered by butyrate in colonic organoids. False discovery rate (FDR)–corrected P<0.05, absolute fold change ≥2, purple dots show downregulated genes by butyrate, pink dots show upregulated genes by butyrate. Gray plots indicate genes that were not differentially expressed (n=5). B, Heat map of gene clusters of differentially expressed genes between control and 3 mmol/L butyrate treatment in organoids (all the genes shown in the heat map, P<0.05). C, mRNA levels of representative genes by quantitative polymerase chain reaction (qPCR; n=5, 0 mmol/L and 3 mmol/L). Fold change relative to control treatment. Values are means±SEM. **P<0.01, ***P<0.001 and ****P<0.0001, unpaired t test. qPCR: total RNA was purified with RNeasy Plus Mini Kit (Qiagen) and reverse-transcribed using iScript Reverse Transcription Supermix (Bio-Rad). Finally, qPCR (ABI Prism 7600) was performed with Taqman universal PCR master mix and specific probes (Ace, interferon-alpha/beta receptor [Ifnar1], Adam17, II1b, interferon regulatory factor-7 [Irf7], Ace2, Tmprss2, high-mobility group protein-1 [Hmgb1], Irk1, Cabin1, and Traf6). Beta-2-microglobulin (B2m) was used as the reference gene for normalization. D, Confocal images showing expression of IFNAR1 and IRF7 (20× objective, scale bar: 50 µm). Immunofluorescence imaging: organoids were fixed, permeabilized, and blocked, followed by incubation with IFNAR1 (Novus) and IRF7 (Invitrogen) antibodies. The organoids were then stained with 4′,6-diamidino-2-phenylindole (DAPI) and Alexa Fluro 488 secondary antibody (Thermo Fisher Scientific) and imaged with a confocal microscope (Olympus IX81). E, Protein levels of IRF7, HMGB1, acetylated-histone H3 (Lys9), and histone H3. Western blot: organoids were treated with 3 and 6 mmol/L butyrate, homogenized in 2% SDS-Tris buffer (pH=7.5). Protein samples (6.7 mg/mL) were separated on 12% TGX precast gels and transferred to Polyvinylidene fluoride membranes (Bio-Rad). Membranes were incubated with HMGB1 (Invitrogen), IRF7 (Invitrogen), acetylated-histone H3 (Lys9; Cell signaling), and histone-H3 antibody (Cell signaling) followed by rabbit and mouse IRDY 680RD secondary antibody (Li-Cor Biosciences). Protein bands were detected using the Odyssey infrared imaging system. F, mRNA levels of Ace2, Cd74, and Irf7 by qPCR in proximal colon of spontaneously hypertensive rats (SHR) and WKY rats (n=6), mean systolic blood pressures 209±5 and 132±6 mm Hg, respectively, measured by tail-cuff plethysmography. Fold change relative to WKY. Gapdh was used as a reference gene for normalization. Values are means±SEM. *P<0.05 and **P<0.01, unpaired t test.

Major histocompatibility complex CIITA (class-II transactivator) activates expression of CD74 isoform-p41, which inhibits SARS-CoV-2 and Ebola virus entry by blocking endosomal entry pathway.4 Butyrate increased expression of Ciita and Cd74 by ≈5× and ≈32×, respectively (Figure [B]). Additionally, Cabin1 (calcineurin binding protein-1) is antiviral in SARS-CoV-2-infected Vero-E6 cells3 and upregulated by butyrate (Figure [B]/[C]).

Another clinical feature of patients with COVID-19 is drastically impaired antiviral immunity with decreased type I and III interferons.5 Our analysis disclosed that TLR (toll-like receptor) signaling pathway, an innate immune system targeting viruses, was significantly enriched by butyrate (normalized enrichment score=1.6329, adjusted P=0.013). Heat map showed elevated expression of genes in this antiviral pathway (Figure [B]) that were inhibited in the gastrointestinal tract of patients with COVID-19 such as interleukin-1-beta (Il1b) and interferon regulatory factor-7 (Irf7).5 Further validation confirmed upregulation of Il1b, Irf7, and interferon-alpha/beta receptor (Ifnar1) by butyrate at mRNA and protein levels (Figure [C]/[D]/[E]). In addition, cluster of differentiation-14 (Cd14) and chemokine ligand-5 (Ccl5) expression were inhibited by butyrate (Figure [B]); blocking their expression is beneficial to patients with COVID-19.6

Butyrate is an HDAC inhibitor that increased acetylation of H3 (histone-H3), whereas it decreased total H3 in colonic organoids (Figure [E]). Additionally, other DEGs may be associated with HDAC inhibition: histone arginine-demethylase Jmjd6, chromatin-remodeling complex members Smarca4 and Arid1a, whose expression exacerbates SARS-CoV-2–induced cell death,3 were downregulated by butyrate (Figure [B]/[C]), suggesting that butyrate may have the potential to prevent cell death by downregulating these genes in gut epithelium.

Hypertension, one of the most common comorbidities with unfavorable outcomes, shares many common pathophysiological features with COVID-19 including inflammation, endothelial dysfunction, gut microbial dysbiosis, decreased butyrate-producing bacteria, increased gut leakiness, and altered renin-angiotensin system.1 Our data showed that mRNA for Ace2 was increased, whereas Cd74 and Irf7 were decreased in proximal colon of spontaneously hypertensive rats (Figure [F]). These data are consistent with the premise of greater infectivity of SARS-COV-2 with hypertension.4,5 Together, they suggest that dysregulation of SARS-COV-2 infection-relevant genes in the colon could alter epithelial-microbiota communication in hypertension. Therefore, gastrointestinal regulation of butyrate may be key in increased comorbidity with hypertension in COVID-19.

In conclusion, we have demonstrated that butyrate downregulates genes essential for SARS-CoV-2 infection but also upregulates TLR and other antiviral pathways. Therefore, this implies that increased risk of COVID-19 in hypertension is partly due to cumulative depletion of butyrate-producing bacteria in the gut. Further studies are warranted to validate this concept using commensal-derived butyrate and effective butyrate derivatives against SARS-CoV-2 in preclinical and early-stage COVID-19 settings.

Nonstandard Abbreviation and Acronyms

ACE

angiotensin-converting enzyme-2

Cabin1

calcineurin binding protein-1

CIITA

class-II transactivator

COVID-19

coronavirus disease 2019

HDAC

histone-deacetylase

HMGB1

high-mobility group protein-1

TLR

toll-like receptor

TMPRSS2

transmembrane protease serine-2

Disclosures None.

Footnotes

For Sources of Funding and Disclosures, see page e14.

Correspondence to: Mohan K. Raizada, Department of Physiology and Functional Genomics, University of Florida College of Medicine, PO Box 100274, Gainesville, FL 32610. Email

References

  • 1. Sharma RK, Stevens BR, Obukhov AG, Grant MB, Oudit GY, Li Q, Richards EM, Pepine CJ, Raizada MK. ACE2 (Angiotensin-Converting Enzyme 2) in cardiopulmonary diseases: ramifications for the control of SARS-CoV-2.Hypertension. 2020; 76:651–661. doi: 10.1161/HYPERTENSIONAHA.120.15595LinkGoogle Scholar
  • 2. Li J, Stevens BR, Richards EM, Raizada MK. SARS-CoV-2 receptor ACE2 (Angiotensin-Converting Enzyme 2) is upregulated in colonic organoids from hypertensive rats.Hypertension. 2020; 76: e26–e28. doi: 10.1161/HYPERTENSIONAHA.120.15725LinkGoogle Scholar
  • 3. Wei J, Alfajaro M, Hanna R, DeWeirdt P, Strine M, Lu-Culligan W, Zhang SM, Graziano V, Schmitz C, Chen J, et al. Genome-wide CRISPR screen reveals host genes that regulate SARS-CoV-2 infection.Biorxiv. 2020. doi: 10.1101/2020.06.16.155101Google Scholar
  • 4. Bruchez A, Sha K, Johnson J, Chen L, Stefani C, McConnell H, Gaucherand L, Prins R, Matreyek KA, Hume AJ, et al. MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses.Science. 2020; 370:241–247. doi: 10.1126/science.abb3753CrossrefMedlineGoogle Scholar
  • 5. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19.Cell. 2020; 181:1036–1045.e9. doi: 10.1016/j.cell.2020.04.026CrossrefMedlineGoogle Scholar
  • 6. Martin TR, Wurfel MM, Zanoni I, Ulevitch R. Targeting innate immunity by blocking CD14: novel approach to control inflammation and organ dysfunction in COVID-19 illness.EBioMedicine. 2020; 57:102836. doi: 10.1016/j.ebiom.2020.102836CrossrefMedlineGoogle Scholar

eLetters(0)

eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.